Imaging test for finding thyroid cancer spread in adults
Tests a PET scan using a radioactive tracer to detect thyroid cancer spread.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Rotterdam and Utrecht, NetherlandsSee the 2 sites
- Trial code
- Registry title
- [18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional
- Record updated
- 2 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with differentiated thyroid cancer. Some have newly found cancer in lymph nodes and are referred for surgery. Others are referred for 131I therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Group 1: newly diagnosed differentiated thyroid cancer with lymph node metastases proven by pathology, referred for surgery. Group 2: differentiated thyroid cancer referred for 131I therapy.
- Earlier treatment
- Cannot have had iodine (for example iodinated contrast agent) or perchlorate within the past 2 months.
Main reasons for not taking part
- Mentally or legally incapacitated
- Pregnant or breastfeeding
- Iodine or perchlorate exposure within the past 2 months
- Takes lithium
- Takes amiodarone
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Group 1: patients with newly diagnosed differentiated thyroid cancer and pathologically proven lymph node metastases thyroid cancer referred for surgical resection - Group 2: patients with differentiated thyroid cancer referred for 131I therapy - The patient has provided written informed consent authorization before participating in the study - The patient is ≥ 18 years old - The patient has an ECOG status grade 0-2
Who cannot take part
- Patient is mentally or legally incapacitated - Patient is pregnant or lactating - Patient has been subjected to an excess of substrates of the sodium iodine symporter such as iodine (e.g. in the form of iodinated contrast agent) or perchlorate within the past 2 months. - Patient takes lithium - Patient takes amiodarone
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
About the trial
What the trial wants to find out
a) To determine the optimal time point acquisition of [18F]TFB PET/CT, b) to determine the value of [18F]TFB PET/CT for detection of (pre-operative) metastatic lymph node(s) in patients with differentiated thyroid cancer and c) to determine the value of [18F]TFB PET/CT for the estimation of radioiodine therapy response in patients with persistent and recurrent differentiated thyroid cancer.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- [18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study
- Plain-language title
- Imaging test for finding thyroid cancer spread in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 2 April 2025